Биология ва тиббиёт муаммолари 2024 №3 (154)

Тема статьи

ANTI-VEGF DRUGS IN THE TREATMENT OF DIABETIC MACULAR OEDEMA (456-461)

Авторы

Khamidullaev Firdavs Faridovich, Normatova Nargiza Mirshovkatovna

Учреждение

1 - Samarkand State Medical University, Republic of Uzbekistan, Samarkand; 2 - Center for the Development of Professional Qualifications of Medical Workers, Republic of Uzbekistan, Tashkent

Аннотация

Diabetic macular oedema (DMO) is one of the main causes of decreased visual acuity in diabetic patients. Intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGF therapy) has been proposed as a novel treatment for DMO. In this review, we summarised the results of randomised clinical trials of VEGF inhibitors in patients with DMO. The results indicate that all inhibitors studied (ranibizumab, bevacizumab, pegaptanib and aflibercept) reduce retinal thickness and improve visual acuity in patients with DMO when used both as monotherapy and in combination with laser treatment. Future studies should determine the optimal duration of anti-VEGF therapy and predictors of its efficacy in DMO.

Ключевые слова

diabetic macular oedema, vascular endothelial growth factor, ranibizumab, bevacizumab, pegaptanib, aflibercept.

Литературы

1. You JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 20l2;35(3):556-564. doi: l0.2337/dcll-l909. 2. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 20l2;l2(4):34254. doi: l0.l007/sll892-0l2-0283-6. 3. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. l9. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. l995;ll3(9):ll44-ll55. PMID: 766l748. 4. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008; (l):CD005656. doi: l0.l002/l465l858.CD005656.pub2. 5. Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 20l2;26(5):435-44l. doi: l0.l0l6/j.jdiacomp.20l2.05.005. 6. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol. 20l2;l53(2):307-3l3. 7. Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, et al. VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type l Diabetes Mellitus. Diabetes Care. 20l3;36(6):l629-l634. doi: l0.2337/dcl2-l95l. 8. Бондарь ИА, Климонтов ВВ. Экскреция инсулиноподобного фактора роста l и фактора роста эндотелия сосудов с мочой у больных сахарным диабетом l-го типа с нефропатией. Проблемы эндокринологии. 2007;53(6):3-7. [Bondar IA, Klimen-tov VV. Renal excretion of insulin-like growth factor l and vascular endothelial growth factor in patients with type l diabetes with nephropathy. Problemy Endocrinologii. 2007;53(6):3-7.]. 9. Nicholson BP, Schachat AP. A review of clinical trials of anti-vegf agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 20l0;248(7):9l5-930. DOI: l0.l007/S004l7-0l0-l3l5-Z. 10. Ford KM, Saint-Geniez M, walshe T, Zahr A, D'Amore PA. Expression and role of vegf in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 20ll;52(l3):9478-9487. DOI: l0.ll67/IOVS.ll-8353. 11. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;l7l(l):53-67. doi: l0.2353/ajpath.2007.06l237. 12. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, et al. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type l diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56(8):2l6l-2l68. doi: l0.2337/db07-0376. 13. Errera FI, Canani LH, Silva ME, Yeh E, Takahashi W, Santos KG, et al. Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30(2):275-279. doi: l0.2337/dc06-l399. 14. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;247(l):2l-26. doi: l0.l007/s004l7-008-09l5-3.